Iridex (IRIX) Net Income towards Common Stockholders (2010 - 2026)
Iridex's (IRIX) quarterly Net Income towards Common Stockholders came in at -$524000.0 in Q2 2026, up 68.92% year-on-year from -$310205.1 in Q2 2025, and down 184.78% quarter-over-quarter from -$184000.0 in Q1 2026.
Iridex (IRIX) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Iridex's Net Income towards Common Stockholders history runs 17 years deep, the most recent figure standing at -$524000.0 for Q2 2026.
- On a quarterly basis, Net Income towards Common Stockholders rose 68.92% year-over-year to -$524000.0 in Q2 2026; TTM through Apr 2026 was -$3.3 million, a 54.06% increase from a year earlier, with the FY2026 full-year figure at -$4.4 million, up 50.19% from the prior year.
- Net Income towards Common Stockholders declined to -$524000.0 in Q2 2026 per IRIX's latest filing, from -$184000.0 in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $6.7 million in Q4 2023 and bottomed at -$3.5 million in Q1 2024.
- The 5-year median for Net Income towards Common Stockholders is -$1.7 million (2023), against an average of -$713500.0.
- Biggest YoY gain for Net Income towards Common Stockholders was 591.46% in 2022; the steepest drop was 260.88% in 2022.
- Year by year, Net Income towards Common Stockholders stood at $6.4 million in 2022, then advanced by 4.96% to $6.7 million in 2023, then tumbled by 112.38% to -$831000.0 in 2024, then slumped by 89.29% to -$1.6 million in 2025, then jumped by 66.69% to -$524000.0 in 2026.
- Per Business Quant, the three latest IRIX Net Income towards Common Stockholders figures stand at -$524000.0 (Q2 2026), -$184000.0 (Q1 2026), and -$1.6 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.35 Bn | 175.06 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 128.79 Bn | 125.91 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 107.93 Bn | 98.71 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 67.82 Bn | 66.37 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 48.03 Bn | 44.36 Bn | 1.29 Bn | - |
| 6 | Dexcom | 28.30 Bn | 27.18 Bn | 750.30 Mn | 199.50 Mn |
| 7 | GE HealthCare Technologies | 27.90 Bn | 25.62 Bn | 1.98 Bn | 411.00 Mn |
| 8 | Smith & Nephew | 27.01 Bn | 26.43 Bn | - | - |
| 9 | Koninklijke Philips | 23.96 Bn | 20.83 Bn | 2.07 Bn | 176.78 Mn |
| 10 | Iridex | 15.41 Mn | 10.81 Mn | 4.74 Mn | -524,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 4, 2026 | -524,000.00 |
| Jan 3, 2026 | -184,000.00 |
| Sep 27, 2025 | -1.57 Mn |
| Jun 28, 2025 | -994,000.00 |
| Mar 29, 2025 | -1.69 Mn |
| Dec 28, 2024 | -831,000.00 |
| Sep 28, 2024 | -1.93 Mn |
| Jun 29, 2024 | -2.68 Mn |
| Mar 30, 2024 | -3.46 Mn |
| Dec 30, 2023 | 6.71 Mn |
| Sep 30, 2023 | -1.75 Mn |
| Jul 1, 2023 | -2.77 Mn |
| Apr 1, 2023 | -2.09 Mn |
| Dec 31, 2022 | 6.40 Mn |
| Oct 1, 2022 | -1.77 Mn |
| Jul 2, 2022 | -2.24 Mn |
| Apr 2, 2022 | -2.39 Mn |
| Jan 1, 2022 | 925,000.00 |
| Oct 2, 2021 | -2.17 Mn |
| Jul 3, 2021 | 1.39 Mn |